GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sensei Biotherapeutics Inc (NAS:SNSE) » Definitions » Asset Turnover

SNSE (Sensei Biotherapeutics) Asset Turnover : 0.00 (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Sensei Biotherapeutics Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Sensei Biotherapeutics's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Sensei Biotherapeutics's Total Assets for the quarter that ended in Sep. 2024 was $56.53 Mil. Therefore, Sensei Biotherapeutics's Asset Turnover for the quarter that ended in Sep. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Sensei Biotherapeutics's annualized ROE % for the quarter that ended in Sep. 2024 was -59.23%. It is also linked to ROA % through Du Pont Formula. Sensei Biotherapeutics's annualized ROA % for the quarter that ended in Sep. 2024 was -51.32%.


Sensei Biotherapeutics Asset Turnover Historical Data

The historical data trend for Sensei Biotherapeutics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sensei Biotherapeutics Asset Turnover Chart

Sensei Biotherapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial - - - - -

Sensei Biotherapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sensei Biotherapeutics's Asset Turnover

For the Biotechnology subindustry, Sensei Biotherapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sensei Biotherapeutics's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sensei Biotherapeutics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Sensei Biotherapeutics's Asset Turnover falls into.



Sensei Biotherapeutics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Sensei Biotherapeutics's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0/( (118.375+74.374)/ 2 )
=0/96.3745
=0.00

Sensei Biotherapeutics's Asset Turnover for the quarter that ended in Sep. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=0/( (59.799+53.254)/ 2 )
=0/56.5265
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Sensei Biotherapeutics  (NAS:SNSE) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Sensei Biotherapeutics's annulized ROE % for the quarter that ended in Sep. 2024 is

ROE %**(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=-29.012/48.9855
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-29.012 / 0)*(0 / 56.5265)*(56.5265/ 48.9855)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.1539
=ROA %*Equity Multiplier
=-51.32 %*1.1539
=-59.23 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Sensei Biotherapeutics's annulized ROA % for the quarter that ended in Sep. 2024 is

ROA %(Q: Sep. 2024 )
=Net Income/Total Assets
=-29.012/56.5265
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-29.012 / 0)*(0 / 56.5265)
=Net Margin %*Asset Turnover
= %*0
=-51.32 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Sensei Biotherapeutics Asset Turnover Related Terms

Thank you for viewing the detailed overview of Sensei Biotherapeutics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Sensei Biotherapeutics Business Description

Traded in Other Exchanges
Address
1405 Research Boulevard, Suite 125, Rockville, MD, USA, 20850
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing highly selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101, SNS-102, SNS-103, SNS-20.
Executives
Stephanie Krebs officer: Chief Business Officer C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH BLVD, SUITE 125, ROCKVILLE MD 20850
John Celebi director, officer: President & CEO SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH BLVD., STE. 125, ROCKVILLE MD 20850
James Peyer director, 10 percent owner C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH BLVD., STE. 125, ROCKVILLE MD 20850
Cambrian Biopharma Inc 10 percent owner, other: See Remarks 228 PARK AVENUE S., #66643, NEW YORK NY 10003
Apeiron Investment Group Ltd. 10 percent owner BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605
Presight Sensei Co-invest Fund, L.p. other: See Explanation of Responses 340 S. LEMON AVE., # 3391, WALNUT CA 91789
Van Der Horst Edward officer: Chief Scientific Officer C/O SENSEI BIOTHERAPEUTICS, INC., 451 D STREET, SUITE 710, BOSTON MA 02210
Presight Co-invest Management, L.l.c. 10 percent owner 340 SOUTH LEMON AVENUE #3391, WALNUT CA 91789
Christian Angermayer 10 percent owner BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605
Patrick Stephen Gallagher officer: Chief Business Officer 66 HAROLD ST, BOSTON MA 02119
William R Ringo director
Thomas G Ricks director H&S VENTURES LLC, 2101 EAST COAST HWY - 3RD FLOOR, CORONA DEL MAR CA 92625
Robert Hamilton Pierce officer: Chief Scientific Officer C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH DR.., STE. 125, ROCKVILLE MD 20850
Kristian Humer director C/O VIRIDIAN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER CO 80301
Jessie English director C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH DR., STE. 125, ROCKVILLE MD 20850